BR112012010249A2 - esterilização de hidrógeis biodegradáveis - Google Patents

esterilização de hidrógeis biodegradáveis

Info

Publication number
BR112012010249A2
BR112012010249A2 BR112012010249A BR112012010249A BR112012010249A2 BR 112012010249 A2 BR112012010249 A2 BR 112012010249A2 BR 112012010249 A BR112012010249 A BR 112012010249A BR 112012010249 A BR112012010249 A BR 112012010249A BR 112012010249 A2 BR112012010249 A2 BR 112012010249A2
Authority
BR
Brazil
Prior art keywords
sterilization
biodegradable
biodegradable water
water
preserved
Prior art date
Application number
BR112012010249A
Other languages
English (en)
Inventor
Harald Rau
Tobias Voigt
Ulrich Hersel
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of BR112012010249A2 publication Critical patent/BR112012010249A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0035—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/10—Ultra-violet radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Colloid Chemistry (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

esterilização de hidrógeis biodegradáveis. a presente invenção refere-se a um processo de esterilização terminal para hidrógeis insolúveis com base em peg biodegradável usando irradiação. a presença de um solvente protetor garante que o hidrogel permaneça funcionalmente intacto com propriedade tridimensionais e físicoquímicas preservadas.
BR112012010249A 2009-10-29 2010-10-28 esterilização de hidrógeis biodegradáveis BR112012010249A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174526 2009-10-29
PCT/EP2010/066404 WO2011051406A1 (en) 2009-10-29 2010-10-28 Sterilization of biodegradable hydrogels

Publications (1)

Publication Number Publication Date
BR112012010249A2 true BR112012010249A2 (pt) 2015-09-22

Family

ID=42040569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010249A BR112012010249A2 (pt) 2009-10-29 2010-10-28 esterilização de hidrógeis biodegradáveis

Country Status (16)

Country Link
US (2) US8986609B2 (pt)
EP (1) EP2493514B1 (pt)
JP (1) JP5893566B2 (pt)
KR (1) KR101756493B1 (pt)
CN (1) CN102686245B (pt)
AU (1) AU2010311421B2 (pt)
BR (1) BR112012010249A2 (pt)
CA (1) CA2776723C (pt)
HK (1) HK1176311A1 (pt)
IL (1) IL218779A (pt)
MX (1) MX2012004499A (pt)
MY (1) MY157640A (pt)
NZ (1) NZ599583A (pt)
RU (1) RU2558847C9 (pt)
WO (1) WO2011051406A1 (pt)
ZA (1) ZA201203032B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
BR112012002280B1 (pt) * 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
MX2012004499A (es) * 2009-10-29 2012-05-29 Ascendis Pharma As Esterilizacion de hidrogeles biodegradables.
AU2011289513B2 (en) 2010-08-09 2014-05-29 C.R. Bard, Inc. Support and cover structures for an ultrasound probe head
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
AU2012314515B2 (en) 2011-09-26 2018-03-15 Preanalytix Gmbh Stabilisation and isolation of extracellular nucleic acids
US9211107B2 (en) 2011-11-07 2015-12-15 C. R. Bard, Inc. Ruggedized ultrasound hydrogel insert
CN104837413B (zh) 2012-06-15 2018-09-11 C·R·巴德股份有限公司 检测超声探测器上可移除帽的装置及方法
ES2614247T3 (es) 2012-09-25 2017-05-30 Qiagen Gmbh Estabilización de muestras biológicas
CN104736623B (zh) * 2012-10-19 2017-09-29 大赛璐塑料株式会社 纤维素酯组合物
MX2015012114A (es) 2013-03-08 2016-01-12 Genzyme Corp Fabricacion continua integrada de principios activos proteinicos terapeuticos.
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
CN105121643A (zh) 2013-03-18 2015-12-02 凯杰有限公司 细胞外核酸的稳定化和分离
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) * 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
US20170274012A1 (en) * 2014-09-03 2017-09-28 Entegrion, Inc. Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads
CN107635470B (zh) 2015-02-25 2021-02-02 决策科学医疗有限责任公司 声学信号传输联接和联接介质
EP3303562B1 (en) 2015-06-08 2023-01-11 Corning Incorporated Drying formulation for hydrogel microcarriers
CN108291250B (zh) * 2015-11-20 2022-05-27 凯杰有限公司 用于稳定细胞外核酸的已灭菌组合物的制备方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2020046602A1 (en) 2018-08-31 2020-03-05 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US11661576B2 (en) 2019-02-05 2023-05-30 Corning Incorporated Packed-bed bioreactor systems and methods of using the same
WO2020181213A1 (en) * 2019-03-06 2020-09-10 Decision Sciences Medical Company, LLC Methods for manufacturing and distributing semi-rigid acoustic coupling articles and packaging for ultrasound imaging
WO2020219705A1 (en) 2019-04-23 2020-10-29 Allan Wegner Semi-rigid acoustic coupling articles for ultrasound diagnostic and treatment applications
US11118151B2 (en) 2019-11-05 2021-09-14 Corning Incorporated Fixed bed bioreactor and methods of using the same
CN111171339B (zh) * 2019-12-18 2022-07-05 青岛大学 一种可注射水凝胶前驱液的制备方法可注射水凝胶及其应用
JP7451732B2 (ja) 2020-02-06 2024-03-18 オキュラ セラピューティクス，インコーポレイテッド 眼疾患を治療するための組成物及び方法
WO2021195163A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
EP4146281A1 (en) 2020-05-04 2023-03-15 Ascendis Pharma A/S Hydrogel irradiation
CN115160599B (zh) * 2022-08-03 2023-06-02 苏州大学 一种按需降解的聚多巴胺交联聚乙二醇水凝胶材料及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
JPH0611290B2 (ja) 1986-11-05 1994-02-16 住友ベークライト株式会社 ポリビニルアルコ−ルゲルのγ線滅菌法
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5705780A (en) 1995-06-02 1998-01-06 Howmedica Inc. Dehydration of hydrogels
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
GB9724055D0 (en) 1997-11-15 1998-01-14 Dow Corning Sa Curable polysiloxane compositions
WO2000033764A1 (en) * 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
AU1249001A (en) 1999-06-11 2001-01-31 Nektar Therapeutics Al, Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
CN1121876C (zh) * 1999-08-12 2003-09-24 中国原子能科学研究院 水凝胶复合型创伤敷料及其辐射合成方法
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1306127B2 (en) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (ja) 2004-10-01 2006-04-13 Kyushu University, National University Corporation 新規ステロイド産生細胞
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
JP2008228744A (ja) * 2005-06-23 2008-10-02 Osaka Prefecture Univ 生体由来移植用組織の石灰化を抑制するための処理方法および処理された組織
EP1840152B1 (en) 2006-03-31 2009-07-08 Sony Deutschland Gmbh A method of forming a crosslinked polymer gel
AU2007267550A1 (en) * 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
AU2008258548B2 (en) 2007-06-08 2014-07-10 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
EP2596805B1 (en) 2008-02-01 2021-10-27 Ascendis Pharma A/S Prodrug comprising a drug-linker conjugate
US8410189B2 (en) * 2008-02-13 2013-04-02 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
US9272048B2 (en) 2008-04-29 2016-03-01 Ascendis Pharma Growth Disorders Division A/S PEGylated recombinant human growth hormone compounds
EP2403537A1 (en) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon alpha carrier prodrugs
BR112012002280B1 (pt) 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
MX2012004499A (es) * 2009-10-29 2012-05-29 Ascendis Pharma As Esterilizacion de hidrogeles biodegradables.

Also Published As

Publication number Publication date
IL218779A (en) 2015-08-31
KR20120123260A (ko) 2012-11-08
ZA201203032B (en) 2013-01-30
MX2012004499A (es) 2012-05-29
RU2558847C2 (ru) 2015-08-10
AU2010311421A1 (en) 2012-04-12
RU2012121915A (ru) 2013-12-10
WO2011051406A1 (en) 2011-05-05
NZ599583A (en) 2013-09-27
EP2493514A1 (en) 2012-09-05
US20150196667A1 (en) 2015-07-16
US8986609B2 (en) 2015-03-24
KR101756493B1 (ko) 2017-07-10
US20120253071A1 (en) 2012-10-04
CA2776723A1 (en) 2011-05-05
AU2010311421B2 (en) 2014-11-20
JP2013509216A (ja) 2013-03-14
US9278139B2 (en) 2016-03-08
CN102686245B (zh) 2015-09-30
IL218779A0 (en) 2012-06-28
CN102686245A (zh) 2012-09-19
MY157640A (en) 2016-07-15
CA2776723C (en) 2018-09-25
HK1176311A1 (zh) 2013-07-26
RU2558847C9 (ru) 2016-07-20
EP2493514B1 (en) 2018-08-22
JP5893566B2 (ja) 2016-03-23

Similar Documents

Publication Publication Date Title
BR112012010249A2 (pt) esterilização de hidrógeis biodegradáveis
CL2018001339A1 (es) Locus óptimos de la soja (divisional de solicitud 1063-2016)
BR112012013504A2 (pt) sistema marcador de evento ingerível integrado com produto farmacêutico
GT201200153A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
CR20120202A (es) Métodos y composiciones para tratar cáncer
UY35812A (es) ?loci de maíz óptimos?.
BRPI0911904A2 (pt) sistema de radiaçao parcial da mama e material biocompativel e biodegradavel para uso em metodo de radiaçao parcial da mama
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CL2012001621A1 (es) Copolimeros aleatorios que contiene un zwiterion tal como la fosforilcolina y por lo menos un agente funcional; y proceso de preparacion de dichos polimeros aleatorios.
WO2009140423A3 (en) Targeted polymer bioconjugates
BRPI1015336A2 (pt) composições para tratamento de tecidos que compreendem polímeros de organossiloxano
UY35814A (es) ?lugares óptimos para la soja?.
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
AR077047A1 (es) Polimeros colorantes cationicos
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
BRPI1006575A2 (pt) composições de proteção contra raios uv e processo para proteção de um tecido queratinoso
BR112012000551A2 (pt) processo para a síntese de conjugados de glicosaminoglicanos (gags) com moléculas biologicamente ativas, conjugados poliméricos e usos relativos dos mesmos.
BR112012019537A2 (pt) dispositivo para o tratamento do canal vaginal e equipamento relevante
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
BRPI0519996A2 (pt) processo para formar atorvastatina amorfa
BR112012028194A2 (pt) composição, e, processo para preparação da composição
BRPI0606812A2 (pt) bisarilhidrazonas, éteres de bisariloxima e seus usos
CO6650413A2 (es) Conjugador para prevención o el tratamiento de la adicción a la nicotina
EA201170821A1 (ru) Энзастаурин для лечения рака
CL2014003467A1 (es) Conjugado polímero-aine que comprende una columna de polímero biodegradable y un aine colgante conjugado a la columna de polimero por medio de un ester arilo; y sistema de suministro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: (REFERENTE AO DESPACHO 7.4 NOTIFICADO NA RPI NO 2449, DE 12/12/2017

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 41/00 (2006.01), A61K 47/69 (2017.01), A61L 2

B15K Others concerning applications: alteration of classification

Ipc: A61L 2/00 (2006.01), A61L 2/08 (2006.01), A61L 2/1

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]